Frankfurt - Delayed Quote EUR
Xenon Pharmaceuticals Inc. (XP0.F)
26.40
0.00
(0.00%)
At close: May 15 at 8:06:22 AM GMT+2
Insider Purchases Last 6 Months
| Shares | Transactions | |
|---|---|---|
| Purchases | 0 | 0 |
| Sales | -- | 0 |
| Net Shares Purchased (Sold) | 0 | 0 |
| Total Insider Shares Held | 196.72k | -- |
| % Net Shares Purchased (Sold) | -- | -- |
Net Institutional Purchases Prior Quarter to Latest Quarter
| Shares | |
|---|---|
| Net Shares Purchased (Sold) | -- |
| % Change in Institutional Shares Held | -- |
Insider Transactions Reported - Last Two Years
| Insider | Transaction | Type | Value | Date |
|---|---|---|---|---|
| MORTIMER IAN C Chief Executive Officer | Sale at price 40.08 - 41.07 per share. | Direct | 2,213,997 | Jan 27, 2025 |
| MORTIMER IAN C Chief Executive Officer | Conversion of Exercise of derivative security at price 17.76 per share. | Direct | 976,800 | Jan 27, 2025 |
| AULIN SHERRY Chief Financial Officer | Sale at price 41.19 - 41.23 per share. | Direct | 770,912 | Dec 18, 2024 |
| AULIN SHERRY Chief Financial Officer | Conversion of Exercise of derivative security at price 9.44 - 11.58 per share. | Direct | 273,393 | Dec 18, 2024 |
| PATOU GARY Director | Sale at price 41.05 - 41.11 per share. | Direct | 200,947 | Nov 22, 2024 |
| PATOU GARY Director | Conversion of Exercise of derivative security at price 7.38 - 13.48 per share. | Direct | 67,429 | Nov 22, 2024 |
| GAROFALO ELIZABETH A. Director | Sale at price 45.69 per share. | Direct | 95,583 | Mar 8, 2024 |
| GAROFALO ELIZABETH A. Director | Conversion of Exercise of derivative security at price 18.56 per share. | Direct | 64,960 | Mar 8, 2024 |
| GANNON STEVEN Director | Sale at price 46.20 - 46.45 per share. | Direct | 601,615 | Mar 7, 2024 |
| SHERRINGTON ROBIN PAUL Officer | Sale at price 46.15 - 46.30 per share. | Direct | 330,290 | Mar 7, 2024 |
| SHERRINGTON ROBIN PAUL Officer | Conversion of Exercise of derivative security at price 9.85 per share. | Direct | 85,114 | Mar 7, 2024 |
| AZAB MOHAMMAD Director | Conversion of Exercise of derivative security at price 9.85 per share. | Direct | 42,552 | Dec 19, 2023 |
| PATOU GARY Director | Sale at price 38.94 - 41.05 per share. | Indirect | 758,983 | Dec 14, 2023 |
| PATOU GARY Director | Sale at price 38.94 - 41.05 per share. | Indirect | 758,983 | Dec 13, 2023 |
| PATOU GARY Director | Conversion of Exercise of derivative security at price 9.00 - 9.85 per share. | Direct | 137,487 | Dec 13, 2023 |
| PATOU GARY Director | Conversion of Exercise of derivative security at price 9.00 - 9.85 per share. | Direct | 137,487 | Dec 13, 2023 |
| SVORONOS DAWN A Director | Sale at price 38.70 per share. | Direct | 967,500 | Aug 24, 2023 |
| PIMSTONE SIMON NEIL Director | Sale at price 38.53 - 39.90 per share. | Direct | 5,104,970 | Jun 1, 2023 |
| PIMSTONE SIMON NEIL Director | Conversion of Exercise of derivative security at price 7.69 - 17.76 per share. | Direct | 2,052,730 | Jun 1, 2023 |
| MORTIMER IAN C Chief Executive Officer | Sale at price 41.37 - 41.49 per share. | Direct | 1,310,931 | May 24, 2023 |
| MORTIMER IAN C Chief Executive Officer | Conversion of Exercise of derivative security at price 9.44 - 9.85 per share. | Direct | 665,536 | May 24, 2023 |
Related Tickers
4DN.F Denali Therapeutics Inc.
12.37
-2.41%
WXXWY WuXi Biologics (Cayman) Inc.
6.08
+2.13%
VIGL Vigil Neuroscience, Inc.
2.3200
-2.11%
BLTE Belite Bio, Inc
67.07
+8.88%
BCDA BioCardia, Inc.
2.3200
-16.85%
2269.HK WuXi Biologics (Cayman) Inc.
23.650
-0.84%
RCUS Arcus Biosciences, Inc.
8.57
+0.35%
KYMR Kymera Therapeutics, Inc.
30.02
+0.91%
CLSD Clearside Biomedical, Inc.
0.8645
+1.23%
MGNX MacroGenics, Inc.
1.5400
-0.65%